Krystal Biotech, Inc. (KRYS)

Krystal Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	95.95	50.7	0	0	0	0
Cost of Revenue	5.51	3.09	0	0	0	0
Gross Profit	90.44	47.61	0	0	0	0
Selling, General & Admin	100.42	98.4	77.74	40.39	15.06	6.47
Research & Development	45.1	46.43	42.46	27.88	17.94	15.62
Other Operating Expenses	12.5	12.5	25	0	0	0
Operating Expenses	158.02	157.33	145.2	68.28	33	22.08
Operating Income	-67.59	-109.73	-145.2	-68.28	-33	-22.08
Interest Expense / Income	0	0	0	1.49	0	0
Other Expense / Income	-126.71	-122.62	-5.22	-0.2	-0.83	-2.99
Pretax Income	59.13	12.9	-139.98	-69.57	-32.17	-19.09
Income Tax	1.97	1.97	0	0	0	0
Net Income	57.16	10.93	-139.98	-69.57	-32.17	-19.09
Shares Outstanding (Basic)	28	27	25	22	19	16
Shares Outstanding (Diluted)	29	28	25	22	19	16
Shares Change	13.92%	8.87%	14.84%	18.15%	18.15%	41.93%
EPS (Basic)	1.98	0.40	-5.49	-3.13	-1.71	-1.20
EPS (Diluted)	1.88	0.39	-5.49	-3.13	-1.71	-1.20
Free Cash Flow	45.56	-0.6	-153.55	-116.27	-40.93	-25.09
Free Cash Flow Per Share	1.61	-0.02	-6.02	-5.24	-2.18	-1.58
Gross Margin	94.25%	93.90%	-	-	-	-
Operating Margin	-70.44%	-216.43%	-	-	-	-
Profit Margin	59.57%	21.56%	-	-	-	-
Free Cash Flow Margin	47.49%	-1.19%	-	-	-	-
Effective Tax Rate	3.32%	15.24%	-	-	-	-
EBITDA	65.04	17.9	-137.33	-66.23	-30.32	-18
EBITDA Margin	67.78%	35.31%	-	-	-	-
Depreciation & Amortization	5.91	5.01	2.64	1.85	1.85	1.09
EBIT	59.13	12.9	-139.98	-68.08	-32.17	-19.09
EBIT Margin	61.62%	25.44%	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).